Drug intelligence / Profile preview

EI-3001

Development stage: Preclinical
Lead developer: Elixiron Immunotherapeutics

Overview

EI-3001 is a preclinical-stage therapeutic candidate being developed by Elixiron Immunotherapeutics. As of early 2024, the program is listed in the company's pipeline with an undisclosed molecular target, modality, and primary indication. Elixiron Immunotherapeutics focuses on immunology and neurodegeneration, particularly targeting pathways involved in chronic inflammation and immune system regulation. EI-3001 represents an early-stage expansion of their portfolio beyond their lead programs in CSF1R inhibition and interferon therapy.

Beyond the preview

Go deeper on EI-3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EI-3001.

Explore the full profile